Hikal gets EIR from USFDA for API unit in Bangalore

04 Nov 2019 Evaluate

Hikal has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its API Unit located at Jigani, Bangalore for the inspection conducted in July 2019. The inspection resulted in one minor FDA Form 483 which was closed out immediately.

Hikal is engaged in R&D, manufacturing and marketing of fine chemicals for the Pharmaceutical and Agrochemical industries.

Hikal Share Price

226.90 0.00 (0.00%)
01-Jan-2026 11:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1711.25
Dr. Reddys Lab 1254.10
Cipla 1503.00
Zydus Lifesciences 911.20
Lupin 2087.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×